NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.<\/p>
The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to urge Vertex to accept NHS England\u2019s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "265418"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-20T09:33:36.433Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England\u2019s latest offer for the supply of Orkambi.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"} , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"} ], "uin" : "265417"} , {"_about" : "http://data.parliament.uk/resources/1132404", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1132404/answer", "answerText" : {"_value" : "
NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.<\/p>
The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to urge Vertex to accept NHS England\u2019s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "265417"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-20T09:33:36.47Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor: Clinical Trials"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"} , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"} ], "uin" : "265418"} , {"_about" : "http://data.parliament.uk/resources/1132424", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1132424/answer", "answerText" : {"_value" : "
On 16 June 2014, a local pilot campaign launched in Devon, Cornwall and Somerset to raise awareness of the signs of skin cancer. It encouraged people to tell their doctor if they noticed any unusual or persistent changes to their skin. It ran until 27 July 2014 and included adverts in the press and on local radio, as well as some direct mail to the target group.<\/p>
<\/p>
Skin Cancer awareness month is an annual awareness campaign that takes place every May. The campaign aims to raise awareness of the dangers of unprotected sun exposure and educate the public about the ways to help prevent skin cancer.<\/p>
The Sunbeds (Regulation) Act 2010 came into force in April 2011 in England and Wales to prohibit under-18s from using sunbeds.<\/p>
<\/p>
Public Health England (PHE) contributed to the revision of the World Health Organization publication \u201cArtificial tanning devices - Public health interventions to manage sunbeds\u201d, which was published in 2017. PHE advises that sunbeds emit ultraviolet radiation, which can cause tanning and sunburn.<\/p>
<\/p>
<\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-20T14:14:40.09Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Skin Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of cases of melanoma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "265456"}
, {"_about" : "http://data.parliament.uk/resources/1132427", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1132427/answer", "answerText" : {"_value" : " As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.<\/p> During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:<\/p> - Seriously ill children likely to have a rare genetic disorder;<\/p> - People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and<\/p> - People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS \u2013 children with cancer, sarcoma and Acute Myeloid Leukaemia.<\/p> <\/p> As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "265509"}
, {"_value" : "265510"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-20T15:34:08.563Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Genomics: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many patients have received whole genome sequencing through the NHS; and how many of those patients had a type of blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
}
, "tablingMemberConstituency" : {"_value" : "Totnes"}
, "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
], "uin" : "265508"}
, {"_about" : "http://data.parliament.uk/resources/1132428", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1132428/answer", "answerText" : {"_value" : " As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.<\/p> During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:<\/p> - Seriously ill children likely to have a rare genetic disorder;<\/p> - People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and<\/p> - People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS \u2013 children with cancer, sarcoma and Acute Myeloid Leukaemia.<\/p> <\/p> As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "265508"}
, {"_value" : "265510"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-20T15:34:08.64Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Genomics: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many patients he estimates will benefit from whole genome sequencing in (a) 2019 and (b) each of the next five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
}
, "tablingMemberConstituency" : {"_value" : "Totnes"}
, "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
], "uin" : "265509"}
, {"_about" : "http://data.parliament.uk/resources/1132429", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1132429/answer", "answerText" : {"_value" : " As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.<\/p> During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:<\/p> - Seriously ill children likely to have a rare genetic disorder;<\/p> - People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and<\/p> - People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS \u2013 children with cancer, sarcoma and Acute Myeloid Leukaemia.<\/p> <\/p> As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "265508"}
, {"_value" : "265509"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-20T15:34:08.717Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Genomics"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, when the NHS Genomic Medicine Service will begin performing whole genome sequencing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
}
, "tablingMemberConstituency" : {"_value" : "Totnes"}
, "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
], "uin" : "265510"}
, {"_about" : "http://data.parliament.uk/resources/1132430", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1132430/answer", "answerText" : {"_value" : " NHS Improvement publishes vacancy data for three staff groups; doctors, nurses and \u2018other staff\u2019. These vacancy statistics are published for England and at the regional level of North, Midlands and East, London and South.<\/p> They do not specifically produce vacancy data for histopathology departments or any vacancy data for each National Health Service hospital or trust.<\/p> NHS Digital published the latest NHS Improvement vacancy data which can be found in the following link:<\/p>